Share on StockTwits
 

Equities research analysts at Aegis lifted their price target on shares of Neostem (NYSE:NBS) from $21.00 to $23.00 in a research note issued to investors on Thursday, AmericanBankingNews.com reports. The firm currently has a “buy” rating on the stock. Aegis’ price objective would suggest a potential upside of 237.24% from the company’s current price.

Shares of Neostem (NYSE:NBS) traded up 7.90% during mid-day trading on Thursday, hitting $7.359. 171,189 shares of the company’s stock traded hands. Neostem has a one year low of $5.00 and a one year high of $9.89. The stock has a 50-day moving average of $6.32 and a 200-day moving average of $6.87. The company’s market cap is $199.7 million.

NeoStem, Inc (NYSE:NBS) is a international biopharmaceutical company with global research and development capabilities and operations in three business units: U.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.